Stentys lands new indications for its self-apposing stent, now marketable for a patient population that represents 10% of all PCIs in Europe.
The Stentys treatment for acute myocardial infarction can now be used in patients with trickier cases, such as those with tapered, dilated or very large vessels or those with bypass grafts. E.U. healthcare regulators also lifted certain contraindications on the device, such as for chronic total occlusions and left main bifurcations.
Princeton, N.J.- and Paris-based Stentys says the new indications allow the medical device company to market its device to a patient group that represents about 10% of all percutaneous coronary interventions in Europe.
CEO and co-founder Gonzague Issenmann said the company is looking to push beyond the traditional heart attack market in Europe, according to prepared remarks.
"Our European customers are using the Stentys Self-Apposing Stent for their patients with atypical vessel anatomies because this is the only available product that solves this unmet need," he said in the statement.
Stentys is hoping a new U.S. clinical trial called Apposition V will help it win pre-market approval for the self-apposing coronary stent.
Here's a look at some of the top funding stories for medical device companies this week.
FDA officials warn against the use of "laparoscopic power morcellation" for the removal of uterine...
Bio-artificial liver maker Vital Therapies takes its IPO even lower, now planning to open at $12 per...
California surgical devices maker Cardica details a public offering of common and preferred stock...